These results are partially supported by the literature reporting the SLC4A4 downregulation in COAD and upregulation in PAAD and PRAD (Chen et al., 2020; Liu Z. et al., 2022; Cappellesso et al., 2022). This evidence concerns the gene SLC4A4 and prostate adenocarcinoma.